Home
Clinical Trials
A Two-decade Mortality Risk A...

A Two-decade Mortality Risk Analysis of Gastrointestinal Carcinoid Neoplasms: an Updated SEER-based Study 2000-2022

Last Updated: 2026-01-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

93481 participants

Study Classification

OBSERVATIONAL

Study Start Date

2000-12-01

Study Completion Date

2022-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinic, Pathologic and Genetic Characterization of Patients With Familial Carcinoid Tumors (Study From the GTE, Groupe d'étude Des Tumeurs Endocrines)

NCT03622333

Small Intestinal Carcinoid Tumors

UNKNOWN NA

Prediction of Gastric Cancer in Intestinal Metaplasia and Atrophic Gastritis

NCT04840056

Gastric Cancer Intestinal Metaplasia Atrophic Gastritis

RECRUITING

Clinical Study on the Accuracy of Real-time AI-assisted Endocytoscopy in the Diagnosis of Colorectal Diminutive Polyps

NCT06791408

Colorectal Polyp

RECRUITING

Esophagogastric Histopathology Potentially Guided Patients Younger Than 50 Years Old to Undergo Colonoscopy Earlier

NCT05832372

Colorectal Neoplasms

UNKNOWN

Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy

NCT06728891

Gastric Carcinoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Carcinoid tumors are rare neuroendocrine tumors with slowly progressive course with the sites are small intestine accounting for 45%, rectum (20%), appendix (17%), colon (11%), and stomach (7%). This study focus on the mortality risk analysis for GI carcinoids due to data insufficiency in the literature. This is a retrospective cohort study based on the Surveillance, Epidemiology, and End Results (SEER) database using SEER\*Stat software covering approximately 28% of the U.S. The inclusion criteria involved all patients with primary malignant GI carcinoid tumor diagnosed between 2000 and 2021 with sequence number 0 or 1. Sequence 0 indicated the patient had only one cancer record while sequence 1 indicated the patient may had developed many cancer records following the first one. In addition, the tumors were restricted to malignant behavior codes (ICD-O-3 Code 3). We used SEER\*Stat software (version 9.0.42.0) to conduct data extraction and statistical analysis. We used the MP-SIR session to calculate the SMR as Observed/Expected (O/E) with a 95% confidence interval (CI) and the excess risk (ER) was per 10,000. Statistical significance was achieved at 0.05. With further analysis, we compared cancer as a cause of death (COD) to other non-cancer COD across different time intervals and primary sites among GI carcinoid tumour.